Indaptus Therapeutics secures new funding and leadership shift

Indaptus Therapeutics ( (INDP) ) has shared an update.

On December 22–23, 2025, Indaptus Therapeutics raised $6 million through a private sale of 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock to investor David E. Lazar at $6.00 per share, securities that are ultimately convertible into a combined 111 million shares of common stock and rank senior to common equity in a liquidation. The company plans to use the proceeds for ongoing operations, severance and general corporate purposes, and has committed to seek shareholder approval by March 31, 2026 for a series of governance and capital structure actions, including authorizing sufficient common shares for conversion, permitting written shareholder consents, adding three Lazar designees to the board and executing a reverse stock split, while granting Lazar participation rights for up to 25% of future equity offerings during a six‑month period. The financing coincided with significant leadership changes: directors Robert Martell and Hila Karah resigned following approval of the offering; Lazar was installed as chairman and co‑chief executive officer and joined on the board by attorney and capital markets specialist Avraham Ben‑Tzvi, while existing director Roger Pomerantz remained on the board and took on key committee roles. In parallel, the company renegotiated terms with its executive team—reducing notice periods and waiving severance in exchange for a mix of cash and equity settlements, securing their voting support for the upcoming shareholder meeting, and accepted the year‑end resignation of its chief medical officer, actions that collectively underscore a broad recapitalization and governance reset aimed at stabilizing the balance sheet and aligning control with the new lead investor.

The most recent analyst rating on (INDP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.

Spark’s Take on INDP Stock

According to Spark, TipRanks’ AI Analyst, INDP is a Underperform.

Indaptus Therapeutics is facing considerable financial and operational difficulties, as highlighted by its poor financial performance with no revenue and continuous losses. The technical analysis further supports a negative outlook, with indicators pointing to bearish momentum. The company’s valuation is unattractive due to its unprofitability and lack of dividends. Collectively, these factors suggest a high-risk investment with limited short-term upside potential.

To see Spark’s full report on INDP stock, click here.

More about Indaptus Therapeutics

Indaptus Therapeutics operates in the biopharmaceutical sector, focusing on the development of immunotherapy-based treatments. The company is publicly listed on Nasdaq and relies on equity financings to support its ongoing operations and clinical programs, making capital access and listing compliance central to its strategy and viability.

Average Trading Volume: 451,648

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.55M

For a thorough assessment of INDP stock, go to TipRanks’ Stock Analysis page.